BIVI BioVie Inc.

BioVie Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.

IPO Year:

Exchange: NASDAQ

Website: biovieinc.com

Recent Analyst Ratings for BioVie Inc.

Date	Price Target	Rating	Analyst
7/22/2022	$7.00	Overweight	Cantor Fitzgerald
11/30/2021	$50.00 → $27.00	Buy	B. Riley Securities

See more ratings

BioVie Inc.

Recent Analyst Ratings for BioVie Inc.

BioVie Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Rogich Sigmund was granted 32,700 shares, increasing direct ownership by 774% to 36,926 units (SEC Form 4)

Director Berman Richard J was granted 34,200 shares, increasing direct ownership by 531% to 40,643 units (SEC Form 4)

SEC Form 4 filed by Director Sherman Michael Edward

SEC Form 4 filed by Director Lang James Paul

SEC Form 4 filed by Director Hariri Robert J

SEC Form 4 filed by Chief Medical Officer Palumbo Joseph M

SEC Form 4 filed by Chief Financial Officer Kim Joanne Wendy

SEC Form 4 filed by President & CEO Do Cuong V

Chief Medical Officer Palumbo Joseph M covered exercise/tax liability with 33,952 shares and was granted 116,000 shares, increasing direct ownership by 221% to 119,196 units (SEC Form 4)

Chief Financial Officer Kim Joanne Wendy covered exercise/tax liability with 23,202 shares and was granted 73,000 shares, increasing direct ownership by 113% to 93,940 units (SEC Form 4)